A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment

Sponsor
Hoffmann-La Roche
Study ID
NCT01990261
Status
Terminated

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.

Study Details

This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.

Key Dates

First listed
Nov 21, 2013
Start date
May 31, 2013
Status verified
Jun 2016
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014

Study Design

Enrollment
33 participants (actual)

Arms

  • Arm: Erlotinib
    Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.

Primary Outcome Measure

Survival Rate at Month 6 [ Time Frame: Month 6 ]

Related Studies